Close Menu

ocular disorder

With the certification, the Silicon Valley-based company aims to roll out its AvaGen test for keratoconus and corneal dystrophies beginning this quarter.

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

They successfully edited the gene in mice in vivo and their approach could also work for a range of heterozygous disease-causing SNPs.

Exome sequencing poorly covers some known disease genes, but identifies novel genes that that Harvard team thinks will help improve panel's diagnostic rate.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.